U of T, McMaster and Genesys Capital Launch Early-Stage Life Sciences Fund
A major new venture capital initiative is set to strengthen Ontario’s life sciences ecosystem by providing early-stage funding to promising health technology startups emerging from academic research. The University of Toronto, McMaster University, Venture Ontario, and veteran healthcare investor Genesys Capital have partnered to establish the Genesys University Seed Fund, a new investment vehicle designed to help transform groundbreaking university discoveries into successful life sciences companies.
The fund aims to bridge one of the biggest challenges facing Canada’s innovation ecosystem: the shortage of early-stage venture capital for life sciences startups. By providing dedicated seed financing, the initiative seeks to ensure that promising scientific discoveries developed in Ontario remain in Canada, ultimately creating new therapies, medical technologies, highly skilled jobs, and long-term economic growth.
Supporting Early-Stage Innovation
The Genesys University Seed Fund has completed its first fundraising close with more than $30 million in commitments. Initial investors include the University of Toronto, McMaster University, Venture Ontario, the Temerty Group, and RBC, with organizers continuing discussions to expand the fund toward a target size of up to $40 million.
The fund will focus on supporting startups in biotechnology, pharmaceuticals, medical devices, diagnostics, and other life sciences sectors that originate from university research. Early-stage financing will allow researchers and entrepreneurs to move promising laboratory discoveries toward commercialization, helping address unmet medical needs while strengthening Canada’s innovation economy.
The initiative comes at a time when governments, universities, and investors are increasingly emphasizing the importance of translating academic research into commercially viable healthcare solutions.
Addressing Canada’s Early-Stage Funding Gap
Ontario is recognized as one of North America’s largest life sciences hubs, employing nearly 76,000 skilled professionals across more than 2,000 companies. The province has earned a global reputation for scientific excellence, particularly in biotechnology, pharmaceuticals, medical technology, and health research.
Despite these strengths, many Canadian startups struggle to secure sufficient seed financing during their earliest stages of development. Compared with innovation ecosystems in the United States—particularly Boston, Cambridge, and Silicon Valley—Canadian entrepreneurs often face fewer venture capital opportunities, making it difficult to grow companies domestically.
As a result, many promising startups relocate outside Canada to obtain investment, taking intellectual property, talent, and economic opportunities with them.
The new fund is specifically designed to reverse this trend by creating a sustainable source of early capital that allows innovative companies to remain headquartered and grow in Ontario.
Building on Proven U.S. Models
The Genesys University Seed Fund follows a model that has proven successful at leading American research institutions, including the Massachusetts Institute of Technology (MIT), the University of Pennsylvania, Harvard University, and the University of California, Berkeley.
University-backed venture funds at these institutions have helped launch hundreds of successful biotechnology and healthcare companies by providing crucial funding during the earliest phases of company formation.
Ontario’s universities hope to replicate that success by strengthening commercialization pathways while creating a thriving local innovation ecosystem.
University of Toronto Focuses on Commercialization
University of Toronto President Melanie A. Woodin emphasized that Canada possesses exceptional scientific talent but often lacks sufficient capital to transform discoveries into commercial products.
She noted that many important innovations risk remaining confined to laboratories because researchers lack access to the financial resources necessary to establish companies, conduct product development, and attract follow-on investment.
According to Woodin, the new partnership represents an important step toward ensuring that Canadian discoveries generate healthcare improvements, employment opportunities, and economic value within Canada rather than abroad.
The University of Toronto has developed one of the world’s strongest university entrepreneurship ecosystems. Over the past five years, it has supported the creation of more than 1,500 venture-backed startups, which collectively have raised more than $14 billion and generated over 20,000 jobs.
Its entrepreneurial network includes 13 accelerator hubs spread across three campuses, while its Health Innovation Hub (H2i) currently supports more than 340 active life sciences ventures.
McMaster University Expands Its Innovation Strategy
McMaster University also views the fund as an important extension of its commercialization efforts.
President Susan Tighe said universities have an increasingly important role in driving Canada’s economic prosperity through innovation. She highlighted McMaster’s long-standing commitment to translating scientific discoveries into real-world healthcare solutions and noted that the institution’s previous seed funding initiatives have already demonstrated encouraging results.
According to Tighe, partnering with Genesys Capital and additional investors will enable McMaster to expand those efforts significantly while helping build a stronger regional life sciences cluster.
McMaster has supported nearly 400 startup companies, many of which have emerged from collaborations involving researchers, clinicians, students, and hospital partners.
One of its most notable success stories is Fusion Pharmaceuticals, which was acquired by AstraZeneca in 2024 for approximately $2 billion, representing one of Canada’s largest university-linked biotechnology exits.
The university also works closely with Hamilton Health Sciences and St. Joseph’s Healthcare Hamilton to accelerate clinical translation of research discoveries into patient care.
Venture Ontario Supports Commercial Growth
The Ontario government is supporting the initiative through Venture Ontario, recognizing early-stage financing as a key driver of economic competitiveness.
Ontario Minister of Economic Development, Job Creation and Trade Vic Fedeli said providing startups with better access to venture capital is essential for converting research breakthroughs into commercially successful businesses.
By bringing together experienced investors, leading research institutions, and healthcare innovators, the new fund aims to strengthen Ontario’s position as one of North America’s leading life sciences regions.
Steve Romanyshyn, President and CEO of Venture Ontario, added that supporting university spinouts delivers both societal benefits and long-term economic returns.
He said the initiative demonstrates Ontario’s commitment to attracting both domestic and international investment while enabling innovative Canadian companies to remain and expand within the province.
Genesys Capital Brings Decades of Experience
Management of the new fund will be led by Genesys Capital, one of Canada’s most experienced life sciences venture capital firms.
Over the past 25 years, Genesys has invested more than $400 million in biotechnology, pharmaceutical, and medical technology companies, helping build numerous successful enterprises throughout Canada.
The firm’s investment portfolio has produced approximately 20 successful exits worth billions of dollars, establishing Genesys as one of Canada’s most influential healthcare investors.
Kelly Holman, Co-Founder and Managing Director of Genesys Capital, described access to capital as one of the most important ingredients for innovation-driven economies.
He noted that Genesys has previously supported several successful companies emerging from both the University of Toronto and McMaster University, and believes the new fund will significantly expand opportunities for the next generation of healthcare entrepreneurs.
Creating a Sustainable Innovation Cycle
Beyond financing startups, the Genesys University Seed Fund has been designed to create a long-term cycle of innovation.
As limited partners in the fund, both universities will receive returns generated by successful investments. Those proceeds will be reinvested into future research, entrepreneurship initiatives, and innovation programs, creating additional opportunities for new companies to emerge.
This self-reinforcing model is intended to build lasting commercialization capacity while continuously strengthening Ontario’s research ecosystem.
Supporting Healthcare Innovation
The fund will prioritize technologies capable of improving patient care across multiple therapeutic areas.
Potential investments may include:
- Biotechnology platforms
- Novel pharmaceuticals
- Cell and gene therapies
- Medical devices
- Digital health technologies
- Artificial intelligence applications in healthcare
- Diagnostics and precision medicine
- Advanced therapeutics
By supporting these emerging technologies at an earlier stage, investors hope to accelerate development timelines while increasing the likelihood that innovative treatments reach patients.
Strengthening Ontario’s Global Position
Ontario officials believe the new venture fund will further establish the province as a leading destination for life sciences commercialization.
Minister of Colleges, Universities, Research Excellence and Security Nolan Quinn said Ontario’s universities consistently produce world-class scientific discoveries, but continued success depends on ensuring innovators have access to the resources necessary to transform ideas into market-ready solutions.
The Genesys University Seed Fund is expected to help researchers launch new companies, create high-value employment opportunities, attract additional private investment, and reinforce Ontario’s international reputation for healthcare innovation.
With its first funding commitments secured and additional fundraising underway, the Genesys University Seed Fund represents a significant new source of capital for Canada’s life sciences sector. By combining the research strengths of two leading universities with the investment expertise of Genesys Capital and support from Venture Ontario and other partners, the initiative aims to accelerate commercialization, retain scientific talent, and foster the development of innovative healthcare companies.
As the fund begins investing in early-stage startups, stakeholders expect it to play an important role in advancing new medical technologies, supporting economic development, and ensuring that scientific discoveries made in Ontario have a greater opportunity to benefit patients both nationally and globally.